RESUMEN
OBJECTIVE: MSB11022 is a biosimilar of adalimumab that has been shown comparable bioequivalence, safety, tolerability, and immunogenicity profiles to the reference adalimumab in healthy volunteers or in patients with psoriasis or rheumatoid arthritis (RA). This is the first study conducted under clinical practice conditions evaluating the switch from reference adalimumab to MSB11022 in patients with RA. METHODS: Retrospective and multicenter study with data from the medical records of patients with RA who switched from reference adalimumab or another biosimilar to MSB11022 and maintained this treatment for at least 6 months. Information registered comes from baseline visit, the moment of the switch, and the follow-up visits. RESULTS: Data from 86 patients were evaluated (median age 63.5 years, 75.6% female, 44.2% had erosive RA). Only 3.5% of the patients received biologic therapy prior to adalimumab. At baseline, median DAS28-CRP was 1.77 (80.2% in remission and 96.5% with low disease activity) and median CDAI was 4.00 (44.2% in remission and 90.7% with low disease activity). After a median follow-up of 8 months, median DAS28-CRP was 1.87 (86.0% in remission and 94.2% with low disease activity) and median CDAI was 4.00 (38.5% in remission and 95.3% with low disease activity). Only three patients experienced pain, swelling, and stinging at the injection site or a locally extensive hematoma in the area of administration. CONCLUSIONS: Adalimumab biosimilar MSB11022 maintained the efficacy benefits provided by previous adalimumab treatments with a safety profile in line with that already described for other biosimilars.
Asunto(s)
Adalimumab , Antirreumáticos , Artritis Reumatoide , Biosimilares Farmacéuticos , Sistema de Registros , Humanos , Adalimumab/administración & dosificación , Adalimumab/uso terapéutico , Adalimumab/efectos adversos , Femenino , Persona de Mediana Edad , Masculino , Artritis Reumatoide/tratamiento farmacológico , Biosimilares Farmacéuticos/administración & dosificación , Biosimilares Farmacéuticos/uso terapéutico , Biosimilares Farmacéuticos/efectos adversos , Antirreumáticos/uso terapéutico , Antirreumáticos/administración & dosificación , Antirreumáticos/efectos adversos , Anciano , España , Estudios Retrospectivos , Resultado del Tratamiento , Sustitución de Medicamentos/estadística & datos numéricos , AdultoRESUMEN
In the present study, an enzymatically hydrolyzed porcine plasma (EHPP) was nutritionally and molecularly characterized. EHPP molecular characterization showed, in contrast to spray-dried plasma (SDP), many peptides with relative molecular masses (Mr) below 8,000, constituting 73% of the protein relative abundance. IIAPPER, a well-known bioactive peptide with anti-inflammatory and antioxidant properties, was identified. In vivo functionality of EHPP was tested in C. elegans and two different mouse models of intestinal inflammation. In C. elegans subjected to lipopolysaccharide exposure, EHPP displayed a substantial anti-inflammatory effect, enhancing survival and motility by 40% and 21.5%, respectively. Similarly, in mice challenged with Staphylococcus aureus enterotoxin B or Escherichia coli O42, EHPP and SDP supplementation (8%) increased body weight and average daily gain while reducing the percentage of regulatory Th lymphocytes. Furthermore, both products mitigated the increase of pro-inflammatory cytokines expression associated with these challenged mouse models. In contrast, some significant differences were observed in markers such as Il-6 and Tnf-α, suggesting that the products may present different action mechanisms. In conclusion, EHPP demonstrated similar beneficial health effects to SDP, potentially attributable to the immunomodulatory and antioxidant activity of its characteristic low Mr bioactive peptides.
Asunto(s)
Caenorhabditis elegans , Animales , Ratones , Porcinos , Caenorhabditis elegans/metabolismo , Hidrólisis , Plasma/metabolismo , Citocinas/metabolismo , Antioxidantes/metabolismo , Lipopolisacáridos , Antiinflamatorios/farmacologíaRESUMEN
Introduction: Fungi that produce mycotoxins can grow on certain food products, such as grains and feed, and can cause a variety of health issues if consumed by animals, including chickens. The use of spray-dried plasma (SDP) is one strategy for combating the health problems caused by mycotoxins. Materials and methods: In the present study, Ross 308 chickens (n = 960) were divided into four treatment groups. T1 group was given a control diet (corn-soybean meal), T2 group was given a control diet +2% SDP, T3 group was given a control diet +2% SDP + mixture mycotoxins and T4 group was givena control diet + mycotoxin mixture. Results: The presence of SDP resulted in weight gain and decreased feed efficiency, whereas mycotoxins resulted in weight loss and increased feed efficiency. SDP increased the thymus' relative weight. The presence of mycotoxins increased the heterophile/lymphocyte ratio. The presence of mycotoxins reduced the production of IL-2 and macrophage inflammatory protein-3 Alpha (MIP-3a), whereas the presence of SDP increased the production of macrophage colony-stimulating Factor (M-CSF). SDP resulted in higher IgA concentrations in the intestinal and tracheal washes than mycotoxin. Finally, adding SDP to broiler diets boosts weight gain, feed efficiency, and immune system development. Discussion: Our results provide information supporting that SDP is a promising tool for improving poultry immunity and performance.
RESUMEN
OBJETIVOS: conocer la efectividad del modelo de atención centrada en la persona en la rehabilitación visual. MÉTODO: se seleccionaron artículos publicados entre 2010 y 2019, recogidos en PUBMED y Web of Science. Se incluyeron aquellos dedicados a la terapia ocupacional y rehabilitación visual de personas con discapacidad visual desde un enfoque de atención centrado en la persona. Finalmente se incluyeron 14 artículos para esta revisión. RESULTADOS: de la búsqueda en PubMed se obtuvieron un total de 490 artículos y de Web of science 40, alcanzando un total de 530 artículos. Después de realizar la lectura del título, se seleccionaron 126 artículos. Tras la lectura de los resúmenes y/o el contenido completo, se excluyeron 112 por no cumplir los objetivos del estudio; resultando elegidos 13 artículos. Las diferentes investigaciones recopiladas justifican que la rehabilitación visual y la terapia ocupacional basadas en el modelo de atención centrada en la persona contribuyen a mejorar la calidad de vida de las personas con baja visión y su autonomía personal. CONCLUSIÓN: son necesarias más investigaciones que evidencien cómo la terapia ocupacional desde una atención centrada en la persona produce resultados positivos en la rehabilitación de personas con baja visión
OBJECTIVE: To know the effectiveness of the person-centered care model in visual rehabilitation. METHOD: Articles published between 2010 and 2019, collected in PUBMED and Web of Science, were selected. Those dedicated to occupational therapy and visual rehabilitation of people with visual disabilities from a person-centered care approach were included. Finally 14 articles were included for this review. RESULTS: A total of 490 articles were obtained from the PubMed search and 40 from Web of science, reaching a total of 530 articles. After reading the title, 126 articles were selected. After reading the abstracts and / or the full content, 112 were excluded because they did not meet the study objectives; resulting in 13 articles chosen. The different studies collected justify that visual rehabilitation and occupational therapy based on the person-centered care model contribute to improving the quality of life of people with low vision and their personal autonomy. CONCLUSION: More research is needed to show how occupational therapy from a person-centered care produces positive results in the rehabilitation of people with low vision
Asunto(s)
Humanos , Autonomía Personal , Evaluación de la Discapacidad , Educación de Personas con Discapacidad Visual/métodos , Resultado del Tratamiento , Atención Dirigida al Paciente/métodos , Trastornos de la Visión/terapia , Servicios de Salud para Personas con Discapacidad , Atención Dirigida al Paciente/organización & administración , Calidad de Vida , Trastornos de la Visión/epidemiología , Trastornos de la Visión/rehabilitación , Actividades CotidianasRESUMEN
No disponible
Asunto(s)
Humanos , Masculino , Adulto , Pulmón/anomalías , Pulmón/diagnóstico por imagen , Dextrocardia/diagnóstico por imagenRESUMEN
El objetivo del presente estudio fue analizar la edad a la que los jugadores de baloncesto de alto rendimiento obtienen los mejores valores de participación y de rendimiento deportivo. Para ello se analizaron el total de jugadores de la liga ACB de baloncesto participantes en la liga regular desde la temporada 2005-2006 hasta la temporada 2017-2018 con el requisito de haber disputado un mínimo de 5 minutos en al menos 5 partidos (n = 2973). Se dividió a la muestra total en cuatro grupos de edad: a) hasta 25 años, b) 25.1 y 28 años, c) de 28.1 a 31 años, y d) mayores de 31 años. De cada uno de los jugadores se registraron los datos estadísticos que fueron clasificados en dos grupos: a) variables relacionadas con la participación, y b) con el rendimiento. Los resultados indican que, en la participación, son los menores de 25 años los que destacan por ser el único rango de edad por debajo de la media general; mientras que, desde la perspectiva del rendimiento, son los jugadores más veteranos los que obtuvieron mejores resultados
The objective of the present study was to analyse the age at which high performance basketball players obtain the best values of participation and sports performance. Total number of players in the ACB basketball league participating in the regular season was analysed from the 2005-2006 season until the 2017-2018 season with the requirement of having played a minimum of 5 minutes in at least 5 matches (n = 2973). The total sample was divided into four age groups: a) up to 25 years, b) 25.1 and 28 years, c) from 28.1 to 31 years, and d) over 31 years. Statistical data were recorded from each of the players and classified into two groups: a) variables related to participation, and b) performance. The results indicate that, in the participation, it is the under-25s who stand out as the only age range below the general average; whereas, from the perspective of performance, it is the oldest players who obtained the best results
O objetivo do presente estudo foi analisar a idade em que jogadores de basquetebol de alto rendimento obtêm os melhores valores de participação e desempenho esportivo. Para este fim, o número total de jogadores de basquete da ACB que participam da liga regular da temporada 2005-2006 até a temporada 2017-2018 foi analisado com a exigência de ter jogado um mínimo de 5 minutos em pelo menos 5 partidas (n = 2973). A amostra total foi dividida em quatro grupos etários: a) até 25 anos, b) 25,1 e 28 anos, c) de 28,1 a 31 anos ed) com mais de 31 anos. Dados estatísticos foram registrados de cada um dos jogadores, os quais foram classificados em dois grupos: a) variáveis relacionadas à participação eb) desempenho. Os resultados indicam que, na participação, são os menores de 25 anos que se destacam como a única faixa etária abaixo da média geral; enquanto, do ponto de vista do desempenho, os jogadores mais veteranos obtiveram os melhores resultados
Asunto(s)
Humanos , Masculino , Adulto Joven , Adulto , Baloncesto/fisiología , Factores de Edad , Rendimiento Atlético/fisiologíaRESUMEN
Objetivo: Este estudio busca describir casos de trauma craneoencefálico debido a heridas por proyectil de arma de fuego, en población civil mayor de 18 años, atendidos en un hospital de referencia y realizar una comparación de los pacientes de acuerdo a los resultados clínicos al egreso. Métodos: Se trata de un estudio descriptivo, observacional, retrospectivo a través de la revisión de historias clínicas de los pacientes mayores de 18 años que ingresaron en la sala de urgencias de la Fundación Valle del Lili en Cali, Colombia con trauma craneoencefálico secundario a heridas por proyectil de arma de fuego, en contexto civil, entre enero del 2010 y febrero del 2016. Se realizó un análisis univariado para determinar factores asociados a muerte y resultados clínicos adversos. Resultados: Se incluyó un total de 95 pacientes con trauma craneoencefálico por heridas por proyectil de arma de fuego en el contexto civil. El 91,6% fue de sexo masculino, el principal contexto fue violencia interpersonal en un 54,7%, el método de transporte más común fue ambulancia terrestre en un 79%, el puntaje de Glasgow (GCS) al ingreso fue 3-8 = 64,2%; 9-12 = 6,3%; 13-15=28,4%. Al ingreso se le tomó TAC simple a 82 (86,3%) pacientes dentro de la primera hora, encontrando una clasificación de Marshall entre I-III en 60,9%, un valor de IV en el 17,8% y entre V-VI en un 4,1%. La trayectoria era penetrante no transfixiante en el 43,2%, transfixiante en el 27,4% y tangencial en el 9,5%. La mortalidad fue del 45,3%, de esta 39% ocurrió en las primeras 24h. Conclusiones: Un mayor compromiso en el estado general del paciente al ingreso determina un pobre pronóstico y mayor probabilidad de muerte en las primeras 24 h
Objective: This study aims to describe cases of traumatic brain injury due to gunshot wounds in civilian population over 18 years of age, treated at a referral hospital in Cali, Colombia and compare the clinical outcomes at discharge. Methods: An observational, descriptive cross-sectional study was conducted by retrospectively collecting clinical data related to adult patients that presented traumatic brain injury due to civil gunshot-wounds and that consulted to the emergency room at Fundación Valle del Lili Hospital in Cali, Colombia between January 2010 and February of 2016. A univariate analysis was performed to determine factors associated with death and adverse clinical outcomes. Results: A total of 95 patients older than 18 years, with traumatic brain injury by gunshot were included in the civil context. The 91.6% were male. The main context was interpersonal violence with 54.7%. The most common method of transportation was by ambulance (79%). The Glasgow score at admission was 3-8 in 64.2% of cases; 9-12 in 6.32% and 13-15 in 28.4%. On admission, head CT scan was performed in 82 (86.3%) patients within the first hour, finding a Marshall-Score between I-III in 60.9%, of IV in 17.8% of cases and a score between V-VI and in 4.1%. The trajectory was non-transfixing penetrating in 43.2%, transfixing in 27.3% and tangential in 9.5%. Mortality was 45.3% in total, 39% died within the first 24hours. Conclusions: A major compromise on admission determines an overall poorer prognosis and a high likelihood of death in the first 24-hours
Asunto(s)
Humanos , Masculino , Femenino , Adulto , Lesiones Traumáticas del Encéfalo/diagnóstico , Lesiones Traumáticas del Encéfalo/mortalidad , Heridas por Arma de Fuego/complicaciones , Pronóstico , Estudios Retrospectivos , 28599 , Lesiones Traumáticas del Encéfalo/complicacionesRESUMEN
Si bien la neumonitis por hipersensibilidad es la complicación pulmonar más frecuentemente descrita durante el tratamiento con metotrexato, existen otras complicaciones de tipo linfoproliferativo e infeccioso que hay que tener en cuenta dentro del diagnóstico diferencial ante una neumopatía en el contexto de dicho tratamiento. La existencia de un riesgo incrementado de desarrollar procesos infecciosos o reactivaciones de microorganismos latentes puede ser similar al observado a lo largo del tratamiento con antagonistas del factor de necrosis tumoral y corticoides. Dentro de ellas, la neumonía por citomegalovirus es una complicación muy severa a tener en cuenta, ya que el diagnóstico acertado y el tratamiento oportuno evitarán un desenlace potencialmente mortal (AU)
Although hypersensitivity pneumonitis is the most common pulmonary complication described during treatment with methotrexate, other complications like lymphoproliferative and infectious disease may be considered in the study of respiratory disease associated to methotrexate. The existence of an increased risk to developing infectious diseases may be similar to that observed during treatment with antagonists of tumor necrosis factor and corticosteroids, where Cytomegalovirus pneumonia is a serious complication; early diagnosis and treatment will prevent a potentially fatal outcome (AU)